Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years.
about
Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomesCorrelation between mammographic and sonographic findings and prognostic factors in patients with node-negative invasive breast cancerSimultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancerPrognostic factors for patients with breast cancers 1cm and smaller.Breast cancer treatment and chemoprevention.Contribution of p53 to metastasis.A nomogram to predict the probability of axillary lymph node metastasis in female patients with breast cancer in China: A nationwide, multicenter, 10-year epidemiological study.Understanding the implications of the breast cancer pathology report: a case study.Prognosis of lymph node-negative breast cancer: Association with clinicopathological factors and tumor associated gene expressionPrediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based modelAdjuvant treatment in node-negative, postmenopausal breast cancer.Breast cancer sentinel node metastases: histopathologic detection and clinical significance.A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancerAdjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?Molecular biology in the diagnosis and prognosis of solid and lymphoid tumors.Isolation and characterization of functional mammary gland stem cells.Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 statusTumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasisConstruction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors.Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.Comparative pathology of breast cancer in a randomised trial of screeningPrognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up.Prognostic factors and recurrence in breast cancer: experience at the national cancer institute of MexicoComparison of five different popular scoring systems to predict nonsentinel lymph node status in patients with metastatic sentinel lymph nodes: a tertiary care center experience.Personalized medicine in breast cancer: a systematic review.Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study.200 Sentinel lymph node biopsies without axillary lymph node dissection -- no axillary recurrences after a 3-year follow-up.Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survivalBreast cancer stem cells: implications for therapy of breast cancer.A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer.Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy.Are two-centimeter breast cancers large or small?Increased Proportion of Variance Explained and Prediction Accuracy of Survival of Breast Cancer Patients with Use of Whole-Genome Multiomic Profiles.Detection of prognostic factors in metastatic breast cancer.Correlation between conductivity and prognostic factors in invasive breast cancer using magnetic resonance electric properties tomography (MREPT).Breast cancer upregulating genes in stromal cells by LINE-1 hypermethylation and micrometastatic detection.Is radiation indicated for young women with early stage, node-negative breast cancer after mastectomy? A multi-institution, retrospective review.Late mortality from pT1N0M0 breast carcinoma.Adjuvant therapy of node-negative breast cancer.Nomogram for prediction of level 2 axillary lymph node metastasis in proven level 1 node-positive breast cancer patients
P2860
Q26778675-73DDAD91-CB17-4F50-811C-C18C74A0BC73Q30462265-600FC022-FB5D-4752-9263-24152123B69AQ33482453-9AD3C8F0-7D97-4C69-96A1-91E826FAA9ACQ33539152-ABF4AFA6-5842-4395-BB10-FB30CA8B1392Q33720741-1AFAD1E8-91A6-4651-88F1-C373B9C18C83Q33776331-0D3606CB-FB41-4EDA-BE38-55B6891704E9Q33798836-45AEE5D6-7481-4107-A4D6-98645A85E62AQ33885989-D361B5BA-E328-4129-9904-13F3FEDC5CEBQ34141617-8D6B90D4-E1DB-40C6-B719-01CE9C472874Q34303233-4903DEF0-2D9E-4CE2-A0C6-D3CB748F5D01Q34385424-E27FA38E-E9E8-4482-BCEE-227D3ADEB283Q34386701-8EAB4318-5387-4408-8BD8-587CDD8E783AQ35034712-BC610447-908B-438E-B252-B3FF5E42197BQ35076216-82631743-DDFB-4330-BB76-DC419A9EF523Q35367195-63441784-EB3D-44B4-A3C4-23DD303A397DQ35548230-99A9D07E-BEFD-485D-8F30-8428979B76FDQ35583711-BBC90BAB-61E5-41CB-9860-ED963C1BA4C2Q35588322-84ECA71B-6F50-422A-8E62-D9F1D7C1BE4FQ35593300-E329FA2A-F061-41E9-AB8E-DE0F9186AA7DQ35835794-6B12B71E-1610-40C6-8A8B-08AFF444222CQ35992802-1A3324FB-F135-4082-8C82-4F6F846BC130Q35994414-FEFF5C43-FC09-46A0-BD72-F1CE930D2002Q36102243-38F5C6AC-98C2-472D-A2AF-835ACABEDD1EQ36234169-429F7F5A-5641-404D-89CC-7D8660CBCA60Q36310182-B662E452-ADA5-4E23-BD98-FE6E74F992E2Q36614283-E2C9625C-79EC-4A9F-B1FC-07FB0DAE24C6Q36694923-FADBB0A8-492A-425E-86F1-06B0CE2D4A87Q36924468-ADE262A8-05C9-4211-867E-D1CE34631205Q36955061-7240D5BF-B39B-47E8-B805-3F3A0584702BQ36962901-338CDB2F-EEDB-41E1-922F-0728A502A63DQ37043609-865259A5-9760-4BAB-A557-E5A2E8AA8B02Q37056869-39032031-9703-4A05-99C5-8EE99B622D0CQ37076838-DC8A5B34-DD54-4FD3-AA4B-C482403AD50CQ37222128-3B7E17E4-EC68-4B37-AC50-51809CA921D8Q38421201-27A13C10-7C11-46EC-A2F6-F4901207BAC8Q38781885-70AA8E00-521A-4641-8DEA-C184061A6C57Q39356667-384F34BF-E16C-4BCE-AC39-8664F2E8B531Q39507969-F89EF3D1-330B-47C0-BB42-457B3CEACD8BQ40441763-F25CA81D-AB6F-4B3C-BC5D-6CB9D3B77595Q42700795-AF1607C9-76B4-4DA1-BB33-33AD817EEA59
P2860
Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh-hant
name
Pathological prognostic factor ...... median follow-up of 18 years.
@en
Pathological prognostic factors in stage I
@nl
type
label
Pathological prognostic factor ...... median follow-up of 18 years.
@en
Pathological prognostic factors in stage I
@nl
prefLabel
Pathological prognostic factor ...... median follow-up of 18 years.
@en
Pathological prognostic factors in stage I
@nl
P2093
P1476
Pathological prognostic factor ...... median follow-up of 18 years.
@en
P2093
P304
P356
10.1200/JCO.1989.7.9.1239
P407
P577
1989-09-01T00:00:00Z